Oncocyte Expands Market Opportunity for VitaGraft™ Kidney
06 Janeiro 2025 - 6:05PM
Oncocyte Corp. (NASDAQ: OCX), a leader in diagnostic technology,
today announced a significant milestone in the advancement of
patient care for kidney transplant patients.
The Molecular Diagnostics program (MolDX) has confirmed the use
of VitaGraft Kidney to monitor patients with newly developed
donor-specific antibodies (dnDSA+) for antibody-mediated rejection
(AMR). This achievement follows the publication of a groundbreaking
study demonstrating VitaGraft Kidney’s ability to detect AMR in
dnDSA+ patients up to 11 months earlier than the current standard
of care.
"Kidney transplant management is changing. There are currently
no approved medications for managing AMR. In the past year, we have
supported two publications that show anti-CD38 therapies have a
chance at treating the disease," said Oncocyte CEO Josh Riggs.
"Assuming the data continue to prove out for those drugs, catching
AMR as early as possible becomes critical, highlighting the
importance of this claims expansion. We have now shown that you can
use our test to both catch AMR early and monitor anti-CD38 therapy.
Eventually, we expect to attach all these claims to our clinical
kitted product that is currently in development."
For context, Oncocyte aims to deliver scientifically proven
molecular diagnostic tests that can be run more affordably and more
quickly at local laboratories. Oncocyte is at a pivotal stage
in commercializing its proprietary diagnostic technology for use in
organ transplant patients. Its technology is designed to enable
local laboratories to run a kitted test that quantifies an
established biomarker, donor-derived cell-free DNA (dd-cfDNA).
Oncocyte’s scientists have played a pivotal role in establishing
dd-cfDNA as a trusted biomarker, and the company now is
commercializing a groundbreaking diagnostic test using this
market-disruptive approach.
An affirmative initial Medicare coverage decision is a key
milestone toward successfully commercializing an assay, and
subsequent claims expansion grows the total addressable market for
an assay. For VitaGraft Kidney, Palmetto GBA, the Medicare
Administrative Contractor for the Centers for Medicare &
Medicaid Services (CMS), first issued a positive coverage decision
in August 2023, confirming that the test had met the criteria for
coverage under MolDX: Molecular Testing for Solid Organ Allograft
Rejection (L38568). (Palmetto administers the MolDX program to
oversee claims processing and determine whether molecular
diagnostic tests meet coverage criteria for Medicare
reimbursement.)
This latest claims expansion grows the total number of testing
opportunities.
Highlights:
- Expanded Medicare coverage under LCD L38568 now includes
VitaGraft Kidney for organ rejection surveillance in dnDSA+
patients.
- Enables earlier detection of antibody-mediated rejection (AMR)
without the need for invasive biopsies.
- Supported by clinical evidence demonstrating VitaGraft Kidney’s
ability to identify AMR up to 11 months earlier than current
protocols.
- Associated with two Z-codes for improved accessibility:
- Z01TT: VitaGraft Kidney – Baseline + First Plasma Test
- Z04D6: VitaGraft Kidney - Subsequent
- Expansion focuses on high-risk patients; the coverage does not
extend to routine surveillance testing.
Citations:
- Company estimates based on Everly M, Rebellato M, Haisch C, et
al. (2013). Incidence and Impact of De Novo Donor-Specific
Alloantibody in Primary Renal Allografts. Transplantation Journal
95(3):410-417. (Link)
About VitaGraft Kidney™VitaGraft Kidney is a
non-invasive, blood-based transplant monitoring test that
quantifies donor-derived cell-free DNA (dd-cfDNA) in kidney
transplant recipients. Utilizing highly precise digital polymerase
chain reaction (digital-PCR) technology, VitaGraft Kidney provides
fast results and reliable diagnostic insights to help clinicians
assess graft health and manage patient care proactively.
About OncocyteOncocyte is a leading diagnostics
technology company. The company’s tests are designed to help
provide clarity and confidence to physicians and their patients.
VitaGraft™ is a clinical blood-based solid organ transplantation
monitoring test. GraftAssure™ is a research use only (RUO)
blood-based solid organ transplantation monitoring test. DetermaIO™
is a gene expression test that assesses the tumor microenvironment
to predict response to immunotherapies. DetermaCNI™ is a
blood-based monitoring tool for monitoring therapeutic efficacy in
cancer patients. For more information about Oncocyte, please visit
https://oncocyte.com/. For more information about our products,
please visit the following web pages:
VitaGraft Kidney™ -
https://oncocyte.com/vitagraft-kidney/
VitaGraft Liver™ -
https://oncocyte.com/vitagraft-liver/GraftAssure™
- https://oncocyte.com/graftassure/
DetermaIO™ -
https://oncocyte.com/determa-io/
DetermaCNI™ -
https://oncocyte.com/determa-cni/
VitaGraft™, GraftAssure™, DetermaIO™, and DetermaCNI™
are trademarks of Oncocyte Corporation.
CONTACT:Jeff RamsonPCG Advisory(646)
863-6893jramson@pcgadvisory.com
Forward-Looking Statements Any statements that
are not historical fact (including but not limited to statements
that contain words such as “will,” “believes,” “plans,”
“anticipates,” “expects,” “estimates,” “may,” and similar
expressions) are forward-looking statements. These statements
include those pertaining to, among other things, Oncocyte’s
commercialization efforts and progress with respect to its
molecular diagnostic tests and its proprietary diagnostic
technology for use in organ transplant patients, the expectation of
successful commercialization and growth of the total addressable
market for VitaGraft Kidney, and other statements about the future
expectations, beliefs, goals, plans, or prospects expressed by
management. Forward-looking statements involve risks and
uncertainties, including, without limitation, risks inherent in the
development and/or commercialization of diagnostic tests or
products, uncertainty in the results of clinical trials or
regulatory approvals, the capacity of Oncocyte’s third-party
supplied blood sample analytic system to provide consistent and
precise analytic results on a commercial scale, potential
interruptions to supply chains, the need and ability to obtain
future capital, maintenance of intellectual property rights in all
applicable jurisdictions, obligations to third parties with respect
to licensed or acquired technology and products, the need to obtain
third party reimbursement for patients’ use of any diagnostic tests
Oncocyte or its subsidiaries commercialize in applicable
jurisdictions, and risks inherent in strategic transactions such as
the potential failure to realize anticipated benefits, legal,
regulatory or political changes in the applicable jurisdictions,
accounting and quality controls, potential greater than estimated
allocations of resources to develop and commercialize technologies,
or potential failure to maintain any laboratory accreditation or
certification. Actual results may differ materially from the
results anticipated in these forward-looking statements and
accordingly such statements should be evaluated together with the
many uncertainties that affect the business of Oncocyte,
particularly those mentioned in the “Risk Factors” and other
cautionary statements found in Oncocyte’s Securities and Exchange
Commission (SEC) filings, which are available from the SEC’s
website. You are cautioned not to place undue reliance on
forward-looking statements, which speak only as of the date on
which they were made. Oncocyte undertakes no obligation to update
such statements to reflect events that occur or circumstances that
exist after the date on which they were made, except as required by
law.
Oncocyte (NASDAQ:OCX)
Gráfico Histórico do Ativo
De Fev 2025 até Mar 2025
Oncocyte (NASDAQ:OCX)
Gráfico Histórico do Ativo
De Mar 2024 até Mar 2025